Targets for future clinical trials in Huntington's disease: What's in the pipeline?

The known genetic cause of Huntington's disease (HD) has fueled considerable progress in understanding its pathobiology and the development of therapeutic approaches aimed at correcting specific changes linked to the causative mutation. Among the most promising is reducing expression of mutant...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Movement disorders 2014-09, Vol.29 (11), p.1434-1445
Hauptverfasser:	Wild, Edward J., Tabrizi, Sarah J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Clinical Trials as Topic - methods Clinical Trials as Topic - trends Gene Silencing Genetic Therapy - methods glial cells HDAC inhibition Histone Deacetylases - genetics Humans Huntingtin Protein Huntington Disease - genetics Huntington Disease - therapy Huntington's disease kynurenine monooxygenase MAPK Movement disorders Nerve Tissue Proteins - genetics Nerve Tissue Proteins - metabolism phosphodiesterase inhibition therapeutics Therapy-Present and Future
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!